美欧融资 biotech板块首页
总表:从这里开始
2025 年起有新融资的美欧 biotech 总表
NewCo 与回报
2025 年起的 NewCo:56 家现状,以及谁真正赚了钱NewCo 上市前后:定价、暴涨、回落与现状NewCo 手上的资产走到哪一步:临床阶段与上市情况中国资产 NewCo 的交易结构
wet-lab 模式
262 家怎么做湿实验:自建、混合还是虚拟?

262 家怎么做湿实验:自建、混合还是虚拟?

整理 2026-11-05 · 来源与可靠度标注见正文
本文目录
  1. 第一部分 综述
  2. 第二部分 70 家逐家详情
  3. 第一组:AI 蛋白与抗体设计(21 家)
  4. 第二组:靶点发现与细胞扰动平台(17 家)
  5. 第三组:新机制小分子与其他发现型公司(32 家)

调研日期:2026-11-02 至 11-05。


第一部分 综述

1. 背景:美国 biotech 一级市场规模

期间 美国 VC 投资额 全球 美国占比
2024 ~$19.5B ~$27.3B 73%
2025 $20.8B $30.5B ~68–71%
2026 H1 $11.5B $16.3B(235 轮) 70%
2026 Q1–Q3 $16.4B $23.9B(385 轮) ~69%

来源:J.P. Morgan / DealForma 季度 deck(只计治疗药物与发现平台,按已披露金额,季度间回溯修订)。结构特征:后期化(B 轮及以后占 2026 H1 的 71%)、大轮集中(H1'26 有 44 轮超过 $100M)、中国来源资产占大药企 $50M+ 预付款许可交易数的 42%。

2. 样本:2025 年起有新融资的美欧 biotech 262 家

  • 数据源:BioPharma Dive 融资追踪(26 家头部 VC 组合,任意金额,截至 2026-10-30)+ Fierce Biotech Fundraising Tracker '25/'26($50M 以上,截至 2026-09-30)。两源按日期 ±14 天加金额去重。
  • 构成:美国 201 家,欧洲 61 家。状态:私有 223、已上市 19、IPO 申请中 2、被收购 10、反向并购 6、不明 2。
  • 局限:$50M 以下且非 26 家 VC 投的轮次基本缺失,欧洲小轮缺得最多;2026 年 10 月只有 BioPharma Dive 部分。

3. wet-lab 模式分类方法

每家公司经检索官网、招聘页(Greenhouse/Lever/Ashby)、SEC 文件、新闻稿、Europe PMC 论文作者单位与方法部分、CEO 访谈,判定四类:

  • in_house:发现阶段(靶点验证、筛选、生物学、化学合成、先导优化、早期动物实验)的湿实验主要在自己实验室。
  • hybrid:自己有实验室,同时有明确命名的外部方承担发现阶段某环节(常见是化学合成给 WuXi/Pharmaron,动物实验给 Charles River)。
  • virtual_outsourced:发现阶段没有自己的实验室。外部包括 CRO/CDMO、授权方或母公司、学术实验室三种。
  • unclear:无法判断。

GLP 毒理和 GMP 生产不作为分类依据,因为几乎所有公司都外包。自有 GMP 的只有 Encoded、Aspen Neuroscience、Neurona、Cytotheryx、Garuda 五家。

两轮调研:首轮覆盖 263 家,其中 104 家只基于官网;第二轮对这 104 家补查招聘页、SEC 文件与论文。最终置信:高 87、中 158、低 17。

4. 分类结果

模式 全样本 262 美国 201 欧洲 61
virtual_outsourced 105(40%) 78 27
in_house 89(34%) 70 19
hybrid 66(25%) 51 15
unclear 2 2 0

5. 剔除 NewCo 后的口径

NewCo 定义:围绕授权引进或收购资产建立、没有自有发现管线的公司(中国资产 NewCo、药企 carve-out、Fairmount/RTW 式资产 NewCo),共 51 家,100% virtual。

模式 非 NewCo 211 美国 160 欧洲 51
in_house 89(42%) 44% 37%
hybrid 66(31%) 32% 29%
virtual_outsourced 54(26%) 23% 33%

剔除后仍成立的规律:临床前/平台公司 in_house 52%;细胞基因治疗 in_house 53%、virtual 仅 12%;AI 公司 hybrid 44%、in_house 37%。

剔除后改变的规律:临床期公司变为三分(33/35/33),不再 virtual 主导;融资 $200M 以上的 26 家 virtual 只剩 15%,大轮 virtual 原来几乎全是 NewCo;小分子公司仍有 46% virtual,内部化学普遍外包。

非 NewCo 但仍 virtual 的 54 家分三类:自有资产但团队只做临床和 CMC 的小公司(Imbria、Fore、Abcuro 等);依附母体或学术实验室的 spin-out(Celea 用 PureTech、Caspian 用 Kura、Tectora 用 Schrödinger、Granite/Helicore 用 Versant Ridgeline、Normunity 在 Yale);真正把发现外包的公司(Isomorphic、QuantX、Third Arc、Corsera)。

6. 公司如何表态

  • 虚拟型公司直接自认:Fore 官网自称 "a virtual biotech company";Oak Hill 在 S-4/A 写明一直以虚拟公司运作、无全职员工;Beeline 的招聘岗位全是外包管理和 CDMO 对接。
  • AI 公司强调 lab-in-the-loop 和专有数据,很少主动提 CRO 使用。Isomorphic 是例外,招聘广告直接把湿实验描述为 externalised 给全球 CRO 网络。
  • 自建型公司不发声明,靠实验室面积、租约和 wet-lab 岗位间接体现。没有公司主动批评外包。
  • BIOSECURE 去风险只出现在招股书风险因素里(Windward、Braveheart、Caldera、Latigo、Lycia)。中国提供方(WuXi 系为主)被点名约 10 处,china_provider=yes 共 48 家,其中 virtual 30、hybrid 17、in_house 1。

7. 70 家发现型公司案例:按业务类型看 wet-lab 模式

从 262 家中挑出 70 家有自有发现平台或新机制管线的公司(剔除 NewCo 和已被收购者),按业务类型分三组,详情见第二部分。

组 家数 代表公司
一、AI 蛋白与抗体设计 21 Chai、Profluent、Isomorphic、Peptilogics、Pinnacle、Mediar、Basecamp、BigHat、Alchemab、Orbis
二、靶点发现与细胞扰动平台 17 Cartography、Soley、Lila、Etiome、Light Horse、Plexium、Auron、Proxima、NewLimit
三、新机制小分子与其他发现型公司 32 Triana、Neomorph、Breakthru、QuantX、Tectora、Matchpoint、Atavistik、Storm、Actithera

三组的 wet-lab 模式差异:

  • AI 蛋白与抗体设计以 hybrid 为主。公司有实验室,但设计吞吐量超过实验产能,验证环节大量依赖外部。Isomorphic 完全外包,BigHat、Lila 自建自动化实验室,两端都有。
  • 靶点发现与细胞扰动平台几乎全是 in_house。扰动数据(Perturb-seq、成像)是这类公司的核心资产,自己产数据,外部只做补充。
  • 新机制小分子分化最大。分子胶、共价、变构这类新机制需要定制 assay,有钱的自建(Triana、Neomorph),纯计算出身的全外包(QuantX、Tectora、Breakthru)。

8. 其他值得注意的事实

  • 2026 年收购完成:Alesta→BioMarin(8-31)、Excellergy→Novartis(6-24)、Actio→Jazz(9-15)、RayThera→Biogen(8-06)、Tubulis→Gilead(5-21,$3.15B 预付)。Merida 已是 Lilly 全资子公司。
  • Electra 于 2026 年 9 月 IPO(Nasdaq: ETRA)。Granite Bio 已进 Phase 1b,Novartis 持有收购期权。
  • 风险信号:Tempero Phase 2 因严重不良事件终止;Helicore Phase 1 因商业原因暂停;Be Biopharma 主试验终止且官网无响应。
  • 被点名最多的外部方是大药企合作方(Lilly 10 家、Novartis 5、BMS 4),其次 WuXi 系(AppTec/Biologics/XDC/CRELUX),印度 Syngene/Aurigene(Third Arc),美国 Charles River、Adimab、MuriGenics、Explora。

第二部分 70 家逐家详情

字段说明:融资 = 2025 年以来的轮次(来源标注 BioPharmaDive / Fierce);wet-lab 模式后括号内为置信度;每家的证据、外部提供方、表态和来源折叠在"展开"里,保留英文调研原文便于核对。每组内按公司名排序。

第一组:AI 蛋白与抗体设计(21 家)

Alchemab Therapeutics

  • 总部:London,UK(Europe)
  • 模态 / 领域:Biologics / Other
  • 融资(2025 起):2025-09-09 Series A $32M [BioPharmaDive];累计披露 $32.0M
  • 状态:私有运营;当前阶段:ATLX-1282 (ALS antibody) Phase 1 (licensed to Eli Lilly, $415M deal May 2025); AI/human-repertoire antibody discovery platform with preclinical pipeline
  • 最新动态:
    • 2026-07-09 GBP25M Series A extension led by British Business Bank
    • 2025-09-09 Phase 1 of ATLX-1282 initiated + $32M financing
    • 2025-05-06 Eli Lilly licenses ATLX-1282 (up to $415M)
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Alloy Therapeutics

  • 总部:Waltham MA,USA(US)
  • 模态 / 领域:Drug discovery / Multiple
  • 融资(2025 起):2026-04-15 Series E $40M [BioPharmaDive];累计披露 $40.0M
  • 状态:私有运营;当前阶段:Platform/services company (ATX-Gx humanized mice, antibody, genetic medicine and cell therapy discovery services; 'biotech ecosystem'); pipeline via partners/spinouts; input lists Phase 3 likely via partnered assets
  • 最新动态:
    • 2026-04-15 40MSeriesE(8VC, JICVGI, EchoCapital)at 1B valuation to scale discovery + preclinical/clinical services and AI/data layer
    • 2026-05 Partnership with Institute for Protein Innovation on antibody discovery
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Ampersand Biomedicines

  • 总部:Cambridge MA,USA(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2025-03-19 Series B $65.0M [Fierce];累计披露 $65.0M
  • 状态:私有运营;当前阶段:Preclinical platform (AND: Address/Navigate/Design multispecific, tissue-targeted biologics); immuno-inflammation and immuno-oncology leads in IND-enabling (2025 plan); obesity discovery partnership (Lilly); no clinical assets found
  • 最新动态:
    • 2025-03-19 $65M Series B incl. Eli Lilly and Flagship; obesity discovery partnership
    • 2026 No 2026 material news found
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Arbor Biotechnologies

  • 总部:Cambridge MA,USA(US)
  • 模态 / 领域:Cell or gene therapy / Multiple
  • 融资(2025 起):2025-03-18 Series C $74M [BioPharmaDive] | 2025-03-18 Series C $73.9M [Fierce];累计披露 $74.0M
  • 状态:私有运营;当前阶段:Lead ABO-101 (LNP-delivered Cas12i2 editor, HAO1, primary hyperoxaluria type 1) in Phase 1/2 redePHine (NCT06839235, recruiting since Jun 2025); preclinical programs incl. undisclosed rare liver disease and ALS; AAV reverse-transcriptase brain-editing research
  • 最新动态:
    • 2026-06-26 MoU with Department of Health Abu Dhabi on gene-editing/genetic medicines (BIO 2026)
    • 2026-05-18 Mathew Pletcher appointed CSO, succeeding John Murphy
    • 2026 ABO-101 EU orphan designation announced with partner Chiesi (date not confirmed)
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Basecamp Research

  • 总部:London,UK(Europe)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2026-09-23 Series C $140.0M [Fierce];累计披露 $140.0M
  • 状态:私有运营;当前阶段:AI platform company (EDEN biological foundation models trained on proprietary BaseData); pipeline of AI-designed therapeutics (programmable genetic medicines / in vivo cell therapy) preclinical, moving toward clinic; no clinical assets
  • 最新动态:
    • 2026-09-23 140MoversubscribedSeriesCledbyS32(NVIDIA, MenloAnthologyFund, Catalio); reported 800M valuation
    • 2026-01 EDEN models released; with UPenn, 97% of EDEN-designed antibiotic peptides active vs WHO priority pathogens in lab testing
    • 2025-01 Opened Kendall Square (Cambridge MA) lab and office; John Finn named CSO; supercomputing cluster
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

BigHat Biosciences

  • 总部:San Mateo CA,USA(US)
  • 模态 / 领域:Biologics / Cancer
  • 融资(2025 起):2026-09-24 Series C $75M [BioPharmaDive];累计披露 $75.0M
  • 状态:私有运营;当前阶段:AI + automated wet lab antibody platform; lead AI-designed ADC in Phase 1 (gastric cancer); clinical-stage; pharma partnerships (Merck, others)
  • 最新动态:
    • 2026-09-24 75MSeriesCco − ledbyDFJGrowthandPremjiInvest(total 223M)
    • 2026-01-07 Business Wire announcement (details not retrieved)
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Chai Discovery

  • 总部:San Francisco CA,USA(US)
  • 模态 / 领域:Drug discovery / Undisclosed
  • 融资(2025 起):2025-08-06 Series A $70.0M [Fierce] | 2025-12-15 Series B $130.0M [Fierce] | 2026-07-14 Series C $400M [BioPharmaDive] | 2026-07-14 Series C $400.0M [Fierce];累计披露 $600.0M
  • 状态:私有运营;当前阶段:Platform (AI foundation models Chai-1/2/3 for molecular/antibody design); no disclosed clinical assets; licenses models to pharma
  • 最新动态:
    • 2026-07-14 Series C reportedly ~400Mat 3.8B valuation
    • 2026-07-13 Novartis collaboration for antibody discovery using Chai-3; argenx partnership reported Jul 15
    • 2026-01 Eli Lilly deal (deploys Chai platform; custom model on Lilly data) alongside $130M Series B
  • wet-lab 模式:混合(hybrid,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Diagonal Therapeutics

  • 总部:Watertown, MA,USA(US)
  • 模态 / 领域:Biologics / Rare diseases
  • 融资(2025 起):2026-01-08 Series B $125M [BioPharmaDive] | 2026-01-08 Series B $125.0M [Fierce];累计披露 $125.0M
  • 状态:私有运营;当前阶段:Lead DIAG723 (ALK1/BMP-receptor clustering agonist antibody) in Phase 1/2 DIAMOND trial for HHT (first patient dosed Jul 2026; FDA Orphan Drug + EMA positive opinion Jun 2025); PAH indication preclinical
  • 最新动态:
    • 2026-10-29: Jeremy Bender named Chair of the Board
    • 2026-07-16: First patient dosed in Phase 1/2 DIAMOND trial of DIAG723 in HHT
    • 2026-05-05: Jonathan Piazza appointed CFO
    • 2026-01-08: $125M oversubscribed Series B co-led by Sanofi Ventures and Janus Henderson
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:HQ 200 Arsenal Yards Blvd Suite 220, Watertown MA - a ~108,000 sq ft lab building (other tenants SQZ, Arkuda, Kymera per Banker & Tradesman). Website describes an integrated computational + experimental engine: ~200,000 antibody sequences per target from immune repertoires, clustered and epitope-binned, representative binders combined into multispecifics 'for experimental testing, then optimized and tested in vitro and in vivo'. ~28-32 employees (aggregators). No named CRO/CDMO; specific bench job postings not retrieved (careers via LinkedIn).
  • 外部提供方:未找到;中国提供方:unknown
  • 公司表态:Co-founder Alex Lugovskoy: platform 'merges computational and experimental approaches' to find rare agonist antibodies (Pharmaceutical Technology).
  • 投资人:Sanofi Ventures, Janus Henderson Investors ; Sanofi Ventures, RA Capital Management, Atlas Venture ; Sanofi Ventures, Janus Henderson Investors, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management L.P., Woodline Partners LP, Atlas Venture, BVF Partners, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, RV Invest, Velosity Ca
  • 来源:

Dualitas

  • 总部:South San Francisco, CA,USA(US)
  • 模态 / 领域:Biologics / Immune diseases
  • 融资(2025 起):2025-09-16 Series A $65M [BioPharmaDive] | 2025-09-16 Series A $65.0M [Fierce];累计披露 $65.0M
  • 状态:私有运营;当前阶段:Preclinical: DTX-103 (allergic) and DTX-102 (autoimmune) bispecifics; DTX-102 clinic expected 2027; DualScreen discovery platform
  • 最新动态:
    • 2026-09-17 Roche research collaboration & license, 36.5Mupfront, upto 1B; Dualitas to functionally screen >300,000 bispecific combinations
    • 2026-06 Karim Dabbagh appointed CEO
    • 2025-09-16 Launched with $65M Series A (Versant, Qiming USA co-lead)
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

EpiBiologics

  • 总部:South San Francisco, CA,USA(US)
  • 模态 / 领域:Biologics / Multiple
  • 融资(2025 起):2026-01-08 Series B $107M [BioPharmaDive] | 2026-01-08 Series B $107.0M [Fierce];累计披露 $107.0M
  • 状态:私有运营;当前阶段:Lead EPI-326 (tissue-selective EGFR-degrading bispecific, EpiTAC platform) in global Phase 1 for EGFR-driven solid tumors incl. NSCLC and HNSCC (first patient dosed Apr 2026); other degrader bispecifics preclinical in oncology/immunology
  • 最新动态:
    • 2026-04-19: First patient dosed with EPI-326 in global Phase 1; Roche Venture Fund joins as investor
    • 2026-01-08: $107M Series B co-led by GV and J&J (JJDC); total raised ~$180M
  • wet-lab 模式:自建(in_house,置信 low)
展开:证据、外部提供方、公司表态、投资人、来源

Helicore Biopharma

  • 总部:California,USA(US)
  • 模态 / 领域:Biologics / Metabolic diseases
  • 融资(2025 起):2025-01-28 Series A $65M [BioPharmaDive] | 2025-01-28 Series A $65.0M [Fierce];累计披露 $65.0M
  • 状态:不明;当前阶段:Lead HCR-188 (anti-GIP ligand mAb) Phase 1 SAD/MAD in overweight/obese volunteers (NCT06845943, single site Herston, Queensland, Australia): primary completion 2025-10-22, then SUSPENDED for 'business decision' (registry last updated 2025-11-26); HCR-488 (GIP binder + biased GLP-1 agonist conjugate) and HCR-688 (GIP binder + amylin agonist) preclinical
  • 最新动态:
    • 2025-11-26: ClinicalTrials.gov: HCR-188 Phase 1 status changed to Suspended (business decision)
    • 2025-03-04: Phase 1 of HCR-188 started (first participant dosed, Australia)
    • 2025-01-28: Emerged from stealth with $65M Series A (Versant, OrbiMed co-lead; Longitude, Wellington)
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Isomorphic Labs

  • 总部:London,UK(Europe)
  • 模态 / 领域:Drug discovery / Undisclosed
  • 融资(2025 起):2025-03-31 Undisclosed $600M [BioPharmaDive] | 2025-03-31 Series N/A $600.0M [Fierce] | 2026-05-12 Series B $2100M [BioPharmaDive] | 2026-05-12 Series B $2100.0M [Fierce];累计披露 $2700.0M
  • 状态:私有运营;当前阶段:AI drug discovery platform (AlphaFold 3 lineage); internal oncology/immunology programs preclinical/IND-enabling; first clinical trial targeted end-2026; Cambridge MA hub hiring clinical supply, translational medicine and clinical contracts roles; Lilly, Novartis partnerships.
  • 最新动态:
    • 2026-10-08: Bloomberg: early talks to raise at $40-50B valuation
    • 2026-05: Raised $2.1B led by Thrive Capital
    • 2026-01: Hassabis: first clinical trials expected by end of 2026
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Maxion Therapeutics

  • 总部:Cambridge,UK(Europe)
  • 模态 / 领域:Biologics / Immune diseases
  • 融资(2025 起):2025-03-17 Series A $72M [BioPharmaDive] | 2025-03-17 Series A $72.0M [Fierce];累计披露 $72.0M
  • 状态:私有运营;当前阶段:KnotBody (knottin-antibody) platform for ion channels/GPCRs; lead MAX001 (Kv1.3 inhibitor, immune-mediated diseases e.g. AD/IBD) preclinical heading to first-in-human (UK ethics favourable opinion Mar 2026).
  • 最新动态:
    • 2026-03-18 UK research ethics committee favourable opinion for MAX001 translational/first-in-human-enabling study
    • 2026-06/07 Hiring translational biology scientists to build disease models
    • 2025-03-17 GBP58M (~$72M) Series A; lab space doubled at Unity Campus
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Mediar Therapeutics

  • 总部:Boston,US(US)
  • 模态 / 领域:Biologics / Immune diseases
  • 融资(2025 起):2026-01-07 Series B $76M [BioPharmaDive];累计披露 $76.0M
  • 状态:私有运营;当前阶段:Anti-fibrotic first-in-class antibodies: MTX-463 (anti-WISP1, IPF) Phase 2 WISPer fully enrolled Oct 2026 (Lilly-licensed); MTX-474 (anti-EphrinB2, diffuse cutaneous SSc) Phase 2 EncompaSSc enrolling; MTX-439 (anti-SMOC2, CKD fibrosis) Phase 1 first cohorts dosed Jun 2026
  • 最新动态:
    • 2026-10-07: Completed enrollment in Phase 2 WISPer trial of MTX-463 in IPF
    • 2026-09-30: PharmaNest digital-pathology collaboration for EncompaSSc Phase 2
    • 2026-08-06: Collaboration and option agreement with Ono Pharmaceutical on fibro-inflammatory diseases
    • 2026-06-23: First cohorts dosed in Phase 1 of MTX-439 (CKD fibrosis)
    • 2026-05-13: Qureight (imaging CRO) to support Phase 2 EncompaSSc
    • 2026-02-03: Alloy Therapeutics completed antibody discovery collaboration for Mediar fibrosis targets
    • 2026-01-07: Oversubscribed $76M Series B
  • wet-lab 模式:混合(hybrid,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:HQ at 201 Brookline Ave, Suite 1002 (10th floor), Boston - an Alexandria-owned life-science lab/office building in Longwood (Suffolk project listing; Wyss Institute also at this address). Team includes VP Head of Antibody Engineering (testimonial on 'generating that next dataset'); Built In listed an onsite 5-days/week lab role covering cell culture and data analysis (first pass). Antibody discovery for new targets outsourced to Alloy Therapeutics (ATX-Gx mice + AI); trial imaging/pathology via Qureight (imaging CRO) and PharmaNest. No open positions currently.
  • 外部提供方:Alloy Therapeutics (antibody discovery) | Qureight (imaging CRO, UK) | PharmaNest (digital pathology) | Eli Lilly (MTX-463 licensee) | Ono Pharmaceutical (collaboration/option partner, Japan);中国提供方:no
  • 公司表态:Homepage: team 'combines deep fibrosis expertise, antibody engineering knowledge, and clinical trial expertise'; CEO Rahul Ballal credits Alloy with accelerating timelines to IND-enabling studies.
  • 投资人:Amplitude Ventures, ICG ; Sofinnova Partners
  • 来源:

Numab Therapeutics

  • 总部:Wadenswil,Switzerland(Europe)
  • 模态 / 领域:Biologics / Multiple
  • 融资(2025 起):2025-01-09 Series C $55M [BioPharmaDive] | 2025-01-10 C extension $54.6M [Fierce];累计披露 $55.0M
  • 状态:私有运营;当前阶段:Multispecific antibody pipeline: NM21-1480 (PD-L1x4-1BBxHSA) clinical (lead at 2025 Series C); NM32 (ROR1-targeted) Phase 1 solid tumors since late 2024; NM81 (IBD) partnered with Kaken heading to clinic; NM49 optioned to Ono. NM26 (AD) sold to J&J via Yellow Jersey ($1.25B, 2024).
  • 最新动态:
    • 2026-10-01 Appointed Rajesh Chopra as Chief Scientific Officer
    • 2025-11 Licensing and co-development deal with Kaken Pharmaceutical for multispecific NM81 in IBD
    • 2025-01 Series C extension to CHF180M total
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Orbis Medicines

  • 总部:Copenhagen,Denmark(Europe)
  • 模态 / 领域:Biologics / Undisclosed
  • 融资(2025 起):2025-01-06 Series A $93M [BioPharmaDive] | 2025-01-06 Series A $93.4M [Fierce];累计披露 $93.0M
  • 状态:私有运营;当前阶段:Platform company (nCycles oral macrocycles via generative AI + high-throughput synthesis); preclinical pipeline, no confirmed clinical asset; Oct 2026 CEO change framed as transition toward clinical stage
  • 最新动态:
    • 2026-09 License deal with Novo Nordisk for oral macrocycles in cardiometabolic disease: up to $1.4B upfront+milestones plus royalties and Novo strategic equity investment
    • 2026-10-27 Appointed Joanne Smith-Farrell, PhD as CEO (single less-reliable source)
    • 2025-01-06 EUR90M Series A (total EUR116M)
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Parabilis Medicines

  • 总部:Boston,US(US)
  • 模态 / 领域:Biologics / Cancer
  • 融资(2025 起):2026-01-08 Series F $305M [BioPharmaDive] | 2026-01-08 Series F $305.0M [Fierce];累计披露 $305.0M
  • 状态:已上市;当前阶段:Lead zolucatetide (FOG-001, Helicon peptide beta-catenin:TCF inhibitor) Phase 1/2 in solid tumors (Australia/China sites); registrational Phase 3 in desmoid tumors planned 1H 2027; preclinical ERG and ARON degrader Helicons; Antibody-Helicon Conjugates with Regeneron
  • 最新动态:
    • 2026-06 Nasdaq IPO (PBLS) priced at $20, above range, upsized
    • 2026-05 Regeneron collaboration on Antibody Helicon Conjugates plus $75M private placement
    • 2026-01-08 $305M Series F led by RA Capital, Fidelity, Janus Henderson
  • wet-lab 模式:混合(hybrid,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Peptilogics

  • 总部:Pittsburgh,US(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2025-10-16 Series B2 $78.0M [Fierce];累计披露 $78.0M
  • 状态:私有运营;当前阶段:Lead zaloganan (PLG0206, engineered anti-biofilm antimicrobial peptide) in pivotal Phase 2/3 RETAIN in prosthetic joint infection after knee arthroplasty (NCT07214311, recruiting since early 2026); Orphan, Fast Track, QIDP; CARB-X-supported controlled-release formulation for trauma bone-injury infection prevention
  • 最新动态:
    • 2026-08-14: Former DePuy Synthes US president Tim Czartoski joined board
    • 2026-03-10: Began pivotal Phase 2/3 RETAIN trial of zaloganan
    • 2025-10-16: 78MSeriesB2(total 120M)
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 low)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:HQ/corporate office 2681 Sidney Street, Pittsburgh (PitchBook calls it corporate office; no lab described). Leadership is development-focused (CEO, COO, CMO, Chief Development Officer, CTO, VP People); only open role is a remote CFO; a Director, Nonclinical posting (remote, Pittsburgh area) oversees microbiology, pharmacology, toxicology and safety studies toward registration/NDA - an oversight role consistent with outsourced nonclinical work. ~20 employees (Built In). No lab, manufacturing or CRO named on site.
  • 外部提供方:CARB-X (funding/partner for controlled-release formulation) | NIAID/NIH (linked on partner page, role not described);中国提供方:unknown
  • 公司表态:Company page describes advancing 'an engineered peptide, zaloganan... a novel anti-biofilm therapeutic'; no operating-model statement.
  • 投资人:Presight Capital, Thiel Bio, Founders Fund, AMR Action Fund, Narya Capital and Beyond Ventures.
  • 来源:

Pinnacle Medicines

  • 总部:Doylestown, PA,USA(US)
  • 模态 / 领域:Biologics / Multiple
  • 融资(2025 起):2026-03-26 Series B $89M [BioPharmaDive];累计披露 $89.0M
  • 状态:私有运营;当前阶段:Preclinical: AI + physics-based de novo designed first-in-class oral peptides against validated biologic targets; lead programs in immunology and cardiometabolic disease, not yet in the clinic; no registered trials
  • 最新动态:
    • 2026-03-26: Oversubscribed 89MSeriesBco − ledbyLAVandForesite(RACapital, OrbiMed, Logos, QuanCapital, HankangCapital); total 134M
  • wet-lab 模式:混合(hybrid,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Profluent

  • 总部:Emeryville,US(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2025-11-19 Series N/A $106.0M [Fierce];累计披露 $106.0M
  • 状态:私有运营;当前阶段:AI protein-design platform ('frontier AI lab for biology'; ProGen models, OpenCRISPR AI-designed editors); no clinical assets; building an internal therapeutic engine in liver-directed genetic medicine (hiring VP Biology & Translational Pharmacology for 2-3 programs to DC nomination); partnered with Lilly on recombinases
  • 最新动态:
    • 2026-09-30: Partnership with BioMarin to design medicines with AI (first-pass item; not re-verified)
    • 2026-04-28: Multi-program Lilly partnership for AI-designed site-specific recombinases: upfront + R&D funding, up to $2.25B milestones plus royalties
    • 2025-11-19: 106Mraiseincl.BezosExpeditions(total 150M)
  • wet-lab 模式:混合(hybrid,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Third Arc Bio

  • 总部:,US(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2026-02-04 A extension $52.0M [Fierce];累计披露 $52.0M
  • 状态:私有运营;当前阶段:Lead ARC101 (CLDN6 x CD3 T-cell engager) in Phase 1 dose escalation in advanced CLDN6+ solid tumors (first patient Mar 2025); additional oncology multispecifics (incl. two masked CD3 TCEs using Adagene SAFEbody) and I&I assets heading to first-in-human.
  • 最新动态:
    • 2026-03-10: ARC101 discovery paper published in mAbs (co-authored with Syngene)
    • 2026-02-04: $52M Series A extension led by a16z with Omega Funds; Series A total $217M
    • 2025-11-13: Licensed Adagene SAFEbody masking tech for two masked CD3 TCEs ($5M upfront, up to $840M milestones)
    • 2025-03-13: First patient dosed in Phase 1 of ARC101
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:Office at 727 Norristown Road, Bldg 8, Suite 320, Lower Gwynedd/Spring House PA (Spring House Innovation Park). The 2026 mAbs ARC101 discovery paper states Third Arc leaders 'planned and directed antibody generation, off-target screening, in vitro and in vivo studies, HDX-MS epitope mapping, non-human primate PK study, and immunogenicity testing conducted at CRO sites', thanks 'the Third Arc Bio team at Syngene International Ltd. and Aurigene Pharmaceutical Services Ltd.' for generating materials and conducting studies; mouse work under Syngene IAEC protocol; NHP study at Envol Biomedical; off-target screen via Retrogenix (Charles River). US staff are leadership plus functions such as Bioanalytical Science.
  • 外部提供方:Syngene International (Bengaluru, India) - dedicated team for antibody generation, in vitro/in vivo studies | Aurigene Pharmaceutical Services (India) - materials/studies | Envol Biomedical - cynomolgus PK study | Charles River (Retrogenix) - off-target cell microarray | Adagene (Suzhou/San Diego) - SAFEbody masking technology licensor;中国提供方:no
  • 公司表态:Discovery paper author statement: studies were 'conducted at CRO sites' under Third Arc direction (mAbs, 2026).
  • 投资人:New investor Andreessen Horowitz (a16z) leads the extension with Omega Funds ; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners, funds managed by abrdn, accounts advised by T. Rowe Price Associates, Marshall Wace, Hillhouse Investment, Galapagos, AbbVie Ventures and Alderline Group.
  • 来源:

第二组:靶点发现与细胞扰动平台(17 家)

Auron Therapeutics

  • 总部:Boston MA,USA(US)
  • 模态 / 领域:Small molecules / Cancer
  • 融资(2025 起):2025-02-04 Series B $27M [BioPharmaDive];累计披露 $27.0M
  • 状态:私有运营;当前阶段:Lead AUTX-703 (oral KAT2A/B heterobifunctional degrader) in Phase 1 in R/R AML/MDS and advanced hematologic malignancies (first patient May 2025; FDA Fast Track); SCLC/NEPC expansion planned; AURIGIN AI/single-cell platform discovery programs. Currently hiring Medical Director (clinical).
  • 最新动态:
    • 2026: J Med Chem paper on discovery of oral KAT2A/B degraders (co-authored with Sai Life Sciences and Paraza Pharma)
    • 2025-10-13: Leadership at TPD & Induced Proximity Summit
    • 2025-05-30: First patient dosed in Phase 1 of AUTX-703
    • 2025-02-24: FDA Fast Track for AUTX-703 in R/R AML
    • 2025-02-04: IND clearance and $27M Series B completion
  • wet-lab 模式:混合(hybrid,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:HQ 55 Chapel Street, Suite 100, Newton MA, within Chapel Bridge Park (250k sq ft R&D/biotech/office campus) where Auron joined as a subtenant (ConnectCRE); website cites a team with expertise in 'biology, medicinal chemistry, and computational science'. 2026 J Med Chem degrader paper (20 authors) includes co-authors from Sai Life Sciences Medicinal Chemistry Dept (Hyderabad, India) and Paraza Pharma (Laval, Canada), indicating outsourced chemistry. Only open role is a Medical Director. In-house lab size not found.
  • 外部提供方:Sai Life Sciences (Hyderabad, India) - medicinal chemistry | Paraza Pharma (Laval, Canada) - discovery chemistry/biology CRO | Leukemia & Lymphoma Society - Therapy Acceleration Program investor;中国提供方:no
  • 公司表态:Website: proprietary single-cell database plus AI/ML platform (AURIGIN) identifies targets, disease models and biomarkers; team spans biology, med chem and computation working with physician-scientists.
  • 投资人:DCVC Bio ; Polaris Partners
  • 来源:

Cartography Biosciences

  • 总部:South San Francisco,USA(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2025-10-02 Series B $67.0M [Fierce];累计披露 $67.0M
  • 状态:私有运营;当前阶段:Lead CBI-1214 (LY6G6D x CD3 T-cell engager, MSS colorectal cancer) Phase 1 (first patient dosed Feb 2026, FDA Fast Track); ATLAS/SUMMIT single-cell antigen-discovery platform with further preclinical programs
  • 最新动态:
    • 2026-02-24 First patient dosed in Phase 1 of CBI-1214
    • 2026-01 Pfizer collaboration to discover tumor-selective antigens using ATLAS/SUMMIT (up to $65M upfront/near-term/option payments)
    • 2025-10-02 $67M Series B led by Pfizer Ventures; later strategic investment from Samsung Ventures
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Character Biosciences

  • 总部:Jersey City, NJ,USA(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2025-03-25 Series B $93.0M [Fierce];累计披露 $93.0M
  • 状态:私有运营;当前阶段:Two dry AMD programs CTX114 (complement inhibitor, geographic atrophy) and CTX203 (lipid regulator) moving into first-in-human/Phase 1 (planned by 2026; no confirmed dosing found); glaucoma discovery program
  • 最新动态:
    • 2025-09 Series B extended to >$110M with Sanofi Ventures; new CMO Robert Kim
    • 2025-03-25 $93M Series B (aMoon, Luma) to take CTX114/CTX203 into Phase 1/2
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Enveda

  • 总部:Boulder, CO,USA(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2026-09-23 Series E $311.0M [Fierce];累计披露 $311.0M
  • 状态:私有运营;当前阶段:Three clinical programs: ENV-6946 (IBD) Phase 1; ENV-294 (atopic dermatitis, asthma) Phase 2a, Phase 2b planned 2026; ENV-308 (metabolic) early clinical with positive readout
  • 最新动态:
    • 2026-09-23 311MSeriesEledbyCatalio( 2B valuation, >$845M raised)
    • 2026-10-01 Additional ENV-294 data at EADV 2026 (planned)
    • 2025-12-09 Initiated parallel Phase 2a trials of ENV-294 in AD and asthma
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Etiome

  • 总部:Cambridge, MA,USA(US)
  • 模态 / 领域:Undisclosed / Multiple
  • 融资(2025 起):2025-04-24 Series A $50M [BioPharmaDive] | 2025-04-24 Series N/A $50.0M [Fierce];累计披露 $50.0M
  • 状态:私有运营;当前阶段:Platform/discovery stage (Temporal Biodynamics: AI over EHR/physiological + molecular data to define disease stages for 'Biostaged Medicines'); focus areas incl. MASH, neurodegeneration (Alzheimer's), autoimmune, precancer; no clinical assets disclosed. Published prospective pilot of physiological foundation model (JAMIA Open, 2026, with Vanderbilt).
  • 最新动态:
    • 2026-01-08: Adrian Rawcliffe (ex-Adaptimmune CEO) appointed CEO and Flagship CEO-Partner
    • 2026: Physiological foundation modeling pilot for subclinical disease published in JAMIA Open (Etiome-funded, with Vanderbilt UMC)
    • 2025-04-24: Unveiled by Flagship Pioneering with $50M
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:Etiome address 55 Cambridge Pkwy, Cambridge MA (Flagship Pioneering building) per JAMIA Open 2026 paper. An Etiome 'Scientist, Neurobiology' posting (Cambridge, via Flagship careers) required hands-on bench work with primary and iPSC-derived neural cells, MEA, sc/snRNA-seq and immunohistology studies. A Harvard TYK2/TDP-43 Nature Comms 2026 author lists present address Etiome. Wet-lab capacity appears to sit alongside a large computational/clinical-data group; lab size not disclosed.
  • 外部提供方:Flagship Pioneering - founder/incubator (shared Flagship Labs infrastructure) | Vanderbilt University Medical Center - clinical data/pilot study collaborator;中国提供方:unknown
  • 公司表态:Flagship launch materials describe defining disease stages from longitudinal human data then developing stage-specific medicines; job posting language indicates in-house experimental validation.
  • 投资人:Flagship Pioneering
  • 来源:

Haya Therapeutics

  • 总部:Lausanne,Switzerland(Europe)
  • 模态 / 领域:Nucleic acids / Multiple
  • 融资(2025 起):2025-05-08 Series A $65M [BioPharmaDive] | 2025-05-08 Series A $65.0M [Fierce];累计披露 $65.0M
  • 状态:私有运营;当前阶段:Lead HTX-001 (ASO vs lncRNA WISPER) for non-obstructive HCM: Ph1a/b dosing (first cohort May 2026), FDA Fast Track Jul 2026; regulatory-genome RNA platform with preclinical programs (incl. oncology).
  • 最新动态:
    • 2026-07-28 FDA Fast Track for HTX-001 in symptomatic nHCM
    • 2026-05-20 First cohort enrolled and dosed in Ph1 of HTX-001
    • 2025-06-03 Moved San Diego operations to Lilly Gateway Labs
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Light Horse Therapeutics

  • 总部:San Diego, CA,USA(US)
  • 模态 / 领域:Small molecules / Cancer
  • 融资(2025 起):2025-01-09 Series A $62M [BioPharmaDive] | 2025-01-09 Series A $62.0M [Fierce];累计披露 $62.0M
  • 状态:私有运营;当前阶段:Discovery/preclinical platform (CRISPR precision gene-editing functional screens to find druggable cryptic domains -> small molecules), oncology focus; no named clinical assets.
  • 最新动态:
    • 2025-01-09 Launched with 62MSeriesAandNovartisresearchcollaboration(25M upfront, up to ~$1B milestones)
    • 2025-11 Featured in C&EN on its function-first approach (per profile; no 2026 material news found)
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Lila Sciences

  • 总部:Cambridge MA,US(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2025-03-10 Seed $200.0M [Fierce] | 2025-09-15 Series A $235.0M [Fierce] | 2025-10-14 A extension $115.0M [Fierce];累计披露 $550.0M
  • 状态:私有运营;当前阶段:Platform ('scientific superintelligence' + autonomous 'AI Science Factories') across life sciences, chemistry, materials; no clinical assets. Early PoC: novel antibodies, carbon-capture materials.
  • 最新动态:
    • 2026-05-19 Named #25 on CNBC 2026 Disruptor 50
    • 2026 Reported in talks to raise at ~$8.5B valuation (StockAnalysis headline; unconfirmed)
    • 2025-10-14/17 Closed 350MSeriesA(NVentures, AnalogDevices, IQT); 550M total; >$1.3B valuation; Alewife Park lease ~235.5-244K sq ft
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

MapLight Therapeutics

  • 总部:Redwood City,US(US)
  • 模态 / 领域:Small molecules / CNS disorders
  • 融资(2025 起):2025-07-28 Series D $373M [BioPharmaDive] | 2025-07-28 Series D $372.5M [Fierce];累计披露 $373.0M
  • 状态:已上市;当前阶段:Lead ML-007C-MA (M1/M4 agonist + peripheral anticholinergic) completed Phase 2 ZEPHYR in schizophrenia (positive/mixed, Jul 2026), Phase 3 ZEPHYR-2 planned; Phase 2 VISTA in Alzheimer's psychosis (readout 2H27). ML-004 (autism) Phase 2 IRIS missed primary endpoint (Jun 2026). ML-009/ML-055/ML-021 preclinical.
  • 最新动态:
    • 2026-07-27 ZEPHYR Phase 2 topline: PANSS -4.5 vs placebo (p=0.015); shares fell on mixed read; EOP2 meeting planned
    • 2026-06-22 IRIS Phase 2 of ML-004 in ASD missed primary endpoint; irritability signal in adolescent subgroup
    • 2025-10-27 IPO on Nasdaq (MPLT) raising ~$250.8M at $17
  • wet-lab 模式:混合(hybrid,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Mestag Therapeutics

  • 总部:Cambridge,UK(Europe)
  • 模态 / 领域:Biologics / Cancer
  • 融资(2025 起):2026-03-17 Undisclosed $40M [BioPharmaDive];累计披露 $40.0M
  • 状态:私有运营;当前阶段:Lead MST-0312 (targeted LTBR agonist, fibroblast immunology, barrier cancers) Phase 1 STARLYS, first patient dosed May 2026; inflammatory-disease programs preclinical.
  • 最新动态:
    • 2026-05-19 First patient dosed with MST-0312 in Phase 1 STARLYS
    • 2026-04-14 MST-0312 data in AACR 2026 late-breaking session
    • 2026-03-16 $40M financing from existing investors (SV, JJDC, Forbion, GV, Northpond); CMO and CDO appointed
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Mirador Therapeutics

  • 总部:San Diego,US(US)
  • 模态 / 领域:Drug discovery / Immune diseases
  • 融资(2025 起):2026-01-12 Series B $250M [BioPharmaDive];累计披露 $250.0M
  • 状态:私有运营;当前阶段:Clinical-stage multi-asset immuno-fibrotic pipeline (Mirador360 precision development engine): Phase 2 IBD platform study (NCT07113522) recruiting; first-in-human studies for MT-201, MT-251, MT-701; antibody discovery and IND-enabling work ongoing
  • 最新动态:
    • 2026-01-12: Announced 250MSeriesB(closedQ32025; T.Rowe, Adage, Fidelity); >650M raised since 2024 launch
    • 2026: Named Fortune Best Small Workplaces / Best Workplaces in BioPharma 2026 (per job ads)
  • wet-lab 模式:混合(hybrid,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

NewLimit

  • 总部:South San Francisco,US(US)
  • 模态 / 领域:Cell or gene therapy / Other
  • 融资(2025 起):2025-05-06 Series B $130.0M [Fierce] | 2026-06-02 Series C $435M [BioPharmaDive] | 2026-06-02 Series C $435.0M [Fierce];累计披露 $565.0M
  • 状态:私有运营;当前阶段:Preclinical epigenetic reprogramming: lead hepatocyte-rejuvenating TF mRNA-LNP (liver) heading to clinic; further programs in immune system and vasculature.
  • 最新动态:
    • 2026-06-02 $435M Series C (per input dataset)
    • 2025-05-06 $130M Series B to push liver mRNA medicine toward clinic
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:Careers: South San Francisco roles in targeted LNP development, in vivo pharmacology, metabolism, immunology, vascular biology, mRNA engineering, analytical development, downstream purification, single-cell technology; website describes testing 'thousands of designs simultaneously using genomics' and retraining AI models on new data.
  • 外部提供方:not found;中国提供方:unknown
  • 公司表态:Website: frontier AI + experimental system - designs TF payloads, tests at scale with genomics, 'retrain[s] models on our new data iteratively' (lab-in-the-loop).
  • 投资人:Kleiner Perkins, Nat Friedman/Daniel Gross, Khosla Ventures, Human Capital, Valor Equity Partners, Dimension, Founders Fund and Brian Armstrong. ; Founders Fund, Thrive Capital, Greenoaks, Quiet Capital ; Eli Lilly and Company ; Founders Fund, Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital and
  • 来源:

Nilo Therapeutics

  • 总部:New York,US(US)
  • 模态 / 领域:Undisclosed / Immune diseases
  • 融资(2025 起):2025-10-08 Series A $101M [BioPharmaDive] | 2025-10-08 Series A $101.0M [Fierce];累计披露 $101.0M
  • 状态:私有运营;当前阶段:Preclinical; immunomodulators targeting brain-body neural circuits that centrally regulate systemic inflammation (autoimmune/inflammatory diseases); no named assets
  • 最新动态:
    • 2025-10-08: Launched with $101M Series A led by The Column Group, DCVC Bio and Lux Capital (Gates Foundation, Alexandria Venture Investments participating); Kim Seth CEO, Laurens Kruidenier CSO
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Odyssey Therapeutics

  • 总部:Boston,US(US)
  • 模态 / 领域:Small molecules / Immune diseases
  • 融资(2025 起):2025-09-10 Series D $213M [BioPharmaDive] | 2025-09-10 Series D $213.0M [Fierce];累计披露 $213.0M
  • 状态:已上市;当前阶段:Lead OD-001 (oral RIPK2 scaffolding inhibitor, UC) Phase 2a topline Apr 2026; Phase 2b mono and Phase 2a combo w/ vedolizumab planned 2H26. OD-002 (SLC15A4 inhibitor, lupus) IND-enabling, CTA 2H26; OD-003 (TNFR2 agonist V-body) preclinical; OD-004 (TSLP/IL-33 bispecific V-body), IRAK4 and IRF5 (w/ Terray) in lead optimization
  • 最新动态:
    • 2026-05-07 Nasdaq IPO (ODTX) priced at 18topofrange, upsized; 279M net incl. concurrent private placement (+$10M overallotment in June)
    • 2026-04 Phase 2a topline induction results for OD-001 in ulcerative colitis
    • 2025-09-10 $213M Series D
  • wet-lab 模式:混合(hybrid,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Plexium

  • 总部:San Diego,US(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2025-08-28 Series N/A $60.1M [Fierce];累计披露 $60.1M
  • 状态:私有运营;当前阶段:Targeted protein degraders: PLX-61639 (oral SMARCA2-selective DCAF16-dependent degrader, SMARCA4-mutant tumors) Phase 1 FIH open to enrollment (NCT07284186; e.g. Duke site start Feb 2026); PLX-66140 (CDK2 cereblon glue, CCNE1-amp ER+/HER2- breast) preclinical; PLX-4545 (IKZF2 glue) completed HV Phase 1 (2025); BRD4 direct-degrader research published 2026
  • 最新动态:
    • 2026-05-07: Presented preclinical efficacy data for PLX-61639 in SMARCA4-mutant tumor models (BioWorld)
    • 2026-04-06: ACS Med Chem Lett paper on BRD4-selective monovalent direct degraders (Plexium, 9330 Scranton Rd)
    • 2025-12-01: First-in-human Phase 1 of PLX-61639 started
    • 2025-08-28: $60.1M financing after workforce reduction; PLX-4545 HV Phase 1 showed Treg reprogramming
  • wet-lab 模式:混合(hybrid,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Proxima

  • 总部:New York, NY,USA(US)
  • 模态 / 领域:Small molecules / Undisclosed
  • 融资(2025 起):2026-01-13 Seed $80M [BioPharmaDive] | 2026-01-13 Seed $80.0M [Fierce];累计披露 $80.0M
  • 状态:私有运营;当前阶段:Platform company (formerly VantAI): Neo all-atom foundation model + NeoLink structural interactomics (XL-MS) for proximity therapeutics/molecular glues; first partner co-developed program targeted to enter clinic in 2026; no disclosed wholly-owned clinical asset
  • 最新动态:
    • 2026-01-13 Rebranded from VantAI to Proxima; $80M oversubscribed seed led by DCVC
    • 2026 Hiring proteomics scientists/principal biologist for Boston lab; partnerships with J&J, BMS, Blueprint Medicines continue
  • wet-lab 模式:混合(hybrid,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Soley Therapeutics

  • 总部:South San Francisco,US(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2026-01-07 Series C $200.0M [Fierce];累计披露 $200.0M
  • 状态:私有运营;当前阶段:Preclinical: SOL-001 (AML) IND and clinic entry targeted 2026 (start not confirmed); SOL-002 oncology in IND-enabling studies; neurodegeneration, metabolic and hair-regeneration programs in discovery/preclinical
  • 最新动态:
    • 2026-01-07 $200M Series C led by Surveyor Capital (Citadel) with HRTG, RWN; Doug Leone Family Fund, Breyer, GordonMD participate
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

第三组:新机制小分子与其他发现型公司(32 家)

Actithera

  • 总部:Oslo,Norway(Europe)
  • 模态 / 领域:Radiopharmaceuticals / Cancer
  • 融资(2025 起):2025-07-09 Series A $76M [BioPharmaDive] | 2025-07-09 Series A $75.5M [Fierce];累计披露 $76.0M
  • 状态:私有运营;当前阶段:Preclinical; lead covalent FAP-targeted radioligand, preparing for clinical entry in 2026 (no confirmed FIH found)
  • 最新动态:
    • 2025-07-09 $75.5M Series A (M Ventures, Hadean, Sofinnova, 4BIO)
    • 2025-12-04 Darshan Dalal appointed CMO
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Atalanta Therapeutics

  • 总部:Boston MA,USA(US)
  • 模态 / 领域:Nucleic acids / CNS disorders
  • 融资(2025 起):2025-01-28 Series B $97M [BioPharmaDive] | 2025-01-28 Series B $97.0M [Fierce];累计披露 $97.0M
  • 状态:私有运营;当前阶段:Renamed Arexera Therapeutics (Oct 2026); lead ATL-101 (di-siRNA, Huntington's disease) expected to enter clinic 2H 2026 with Ph1 data 2027; ATL-201 (KCNT1 epilepsy) preclinical; di-siRNA and bispecific siRNA platforms
  • 最新动态:
    • 2026-10-15 Renamed Arexera Therapeutics; pipeline update building Huntington's franchise
    • 2026-05-14 Investor RiverVest notes ATL-101 to enter clinic 2H 2026
    • 2025-01-28 $97M Series B
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Atavistik Bio

  • 总部:Cambridge MA,USA(US)
  • 模态 / 领域:Small molecules / Other
  • 融资(2025 起):2025-12-18 Series B $120.0M [Fierce] | 2026-03-05 Series B $40M [BioPharmaDive];累计披露 $160.0M
  • 状态:私有运营;当前阶段:Lead ATV-1601 (oral allosteric AKT1-selective inhibitor): Phase 1 in AKT1 E17K cancers (NCT07038369, active not recruiting); HHT program entering clinic 2026 (reported IND clearance + Fast Track, single secondary source); JAK2 V617F-selective program (MPN) preclinical
  • 最新动态:
    • 2026-06 Reported FDA IND clearance and Fast Track for ATV-1601 in HHT (aggregator, unconfirmed)
    • 2026-03-05 ~$40M Series B extension led by RA Capital (round total $160M)
    • 2025-12-18 $120M Series B
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Aviceda Therapeutics

  • 总部:Cambridge MA,USA(US)
  • 模态 / 领域:Small molecules / Other
  • 融资(2025 起):2025-01-07 Series C $208M [BioPharmaDive] | 2025-01-07 Series C $207.5M [Fierce];累计披露 $208.0M
  • 状态:私有运营;当前阶段:Lead AVD-104 (intravitreal glycan-coated nanoparticle, Siglec agonist, geographic atrophy): Phase 2b SIGLEC missed primary endpoint vs avacincaptad pegol (Dec 2025); company plans two randomized sham-controlled Phase 3 studies (initiation guided for 2026; start not confirmed as of Nov 2026)
  • 最新动态:
    • 2025-12-15: Phase 2b SIGLEC topline: no stat-sig difference in GA growth vs monthly avacincaptad pegol; company cites baseline lesion imbalances; plans two Phase 3 trials, design informed by OCT analyses and regulatory interactions
    • 2025-01-07: $207.5M Series C to support pivotal Phase 3 of AVD-104
  • wet-lab 模式:混合(hybrid,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Be Biopharma

  • 总部:Cambridge MA,USA(US)
  • 模态 / 领域:Cell or gene therapy / Other
  • 融资(2025 起):2025-01-15 Series C $10M [BioPharmaDive];累计披露 $10.0M
  • 状态:私有运营;当前阶段:Engineered B cell medicines (BCM) platform: lead BE-101 (CRISPR-engineered autologous B cells secreting FIX-Padua, hemophilia B) Phase 1/2 BeCoMe-9 TERMINATED (strategic business decision, not safety; 5 of 24 planned pts; CT.gov update 2026-06-15); BE-102 (ALP-producing BCM, hypophosphatasia) guided to enter clinical development in 2026 - no confirmation found.
  • 最新动态:
    • 2026-06-15: BeCoMe-9 Phase 1/2 of BE-101 listed as terminated for strategic business reasons (confirmed to Endpoints)
    • 2026: BE-101 preclinical package published in Molecular Therapy (FIX-Padua engineered B cells)
    • 2025-02-06: $82M financing (Series C close) for BE-101 and new BE-102 program; some staff departures as resources shifted to product development
  • wet-lab 模式:混合(hybrid,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Breakthru Medicine

  • 总部:Phoenix AZ,USA(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2026-01-29 Series A $60.0M [Fierce];累计披露 $60.0M
  • 状态:私有运营;当前阶段:Preclinical oncology (aggressive solid tumors): small molecules, molecular glues and ADC payloads; lead program targeting clinical trials in early 2027; no clinical assets yet.
  • 最新动态:
    • 2026-01-29: Emerged from stealth with $60M Series A (after undisclosed seed); investors include Fred Eshelman, Mark Gergen (chair), Dave Morehead
    • 2026-08: InBusinessPHX profile: office space at Phoenix Bioscience Core; lead program to clinic 2027
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

BreezeBio

  • 总部:South San Francisco CA,USA(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2026-02-25 Series B $60.0M [Fierce];累计披露 $60.0M
  • 状态:私有运营;当前阶段:Preclinical: lead BRZ-101 (NanoGalaxy hydrophilic nanoparticle delivering mRNA-encoded autoantigens + tolerogenic co-factors, type 1 diabetes) entering IND-enabling studies; no clinical assets
  • 最新动态:
    • 2026-05-26 Formed Scientific Advisory Board to guide BRZ-101 and NanoGalaxy platform
    • 2026-02-25 Rebranded from GenEdit to BreezeBio with $60M Series B; pivot from delivery-platform partnering to internal pipeline
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Charm Therapeutics

  • 总部:London,UK(Europe)
  • 模态 / 领域:Small molecules / Cancer
  • 融资(2025 起):2025-09-02 Series B $80M [BioPharmaDive] | 2025-09-02 Series B $80.0M [Fierce];累计披露 $80.0M
  • 状态:私有运营;当前阶段:Lead CHM-029 (AI/DragonFold-designed menin inhibitor, KMT2Ar/NPM1m AML) approaching first-in-human (Phase 1 projected ~Aug 2026; no dosing confirmation found)
  • 最新动态:
    • 2026-08-18 Formed Clinical Advisory Board for CHM-029, advancing toward clinic in 2026
    • 2025-09-02 $80M Series B co-led by NEA and SR One (NVIDIA-backed)
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

City Therapeutics

  • 总部:Cambridge, MA,USA(US)
  • 模态 / 领域:Nucleic acids / Other
  • 融资(2025 起):2026-06-08 Series B $100M [BioPharmaDive] | 2026-06-08 Series B $99.5M [Fierce];累计披露 $100.0M
  • 状态:已上市;当前阶段:Nasdaq: CTY (IPO Oct 2026). Lead CITY-FXI (RNAi vs Factor XI) in Phase 1, Phase 2 TKA study planned; CITY-RBP4 (Stargardt/GA, LRP1-ligand eye delivery) Phase 1 start late 2026; CITY-TFR2 (anemia of myelofibrosis) China IIT late 2026 and IND/Phase 1/2 early 2027; cityRNA triggers CITY-O02/CITY-C02 (ocular/CNS); collaborations with Bausch + Lomb (eye) and Biogen (CNS)
  • 最新动态:
    • 2026-10-16: 424B4 filed; IPO priced at 18(upsized), 230M incl. overallotment, Nasdaq: CTY
    • 2026-06-08: $99.5M Series B (Viking, Sofinnova, ARCH, Fidelity et al.)
  • wet-lab 模式:混合(hybrid,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:424B4 (Oct 2026): HQ leases ~51,726 sq ft of 'office and laboratory space' at 399 Binney Street, Cambridge MA (term to Sept 2031); 81 FTEs as of Sept 1, 2026, 71 in R&D. 'We do not own or operate ... any manufacturing facilities' - relies on third-party CDMOs for preclinical and clinical supply; 'rely on third parties to conduct certain research and preclinical testing activities' and CROs for trials, including a China IIT for CITY-TFR2.
  • 外部提供方:Unnamed CDMOs (oligonucleotide drug substance/product) | Unnamed CROs, medical institutions (incl. China investigator-initiated trial for CITY-TFR2) | Bausch + Lomb (eye RNAi collaboration) | Biogen (CNS RNAi collaboration);中国提供方:unknown
  • 公司表态:Prospectus: relies on 'well-established third-party contract development and manufacturing organizations' and employs staff to oversee contract manufacturing/testing, while running platform R&D in its Cambridge labs.
  • 投资人:Arch Venture Partners, Sofinnova Investments ; Viking Global Investors, Sofinnova Investments, Casdin Capital, NYBC Ventures, ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures and others.
  • 来源:

Excellergy

  • 总部:California (Bay Area),USA(US)
  • 模态 / 领域:Biologics / Immune diseases
  • 融资(2025 起):2025-10-13 Series A $70M [BioPharmaDive] | 2025-10-13 Series A $70.0M [Fierce];累计披露 $70.0M
  • 状态:已被收购;当前阶段:Acquired by Novartis (wholly owned subsidiary since 2026-06-24). Lead Exl-111 (half-life-extended trifunctional anti-IgE 'ECRI' antibody) in Phase 1; next-gen candidates preclinical
  • 最新动态:
    • 2026-06-24: Excellergy became an indirect wholly owned subsidiary of Novartis AG (deal closed)
    • 2026-03-27: Novartis agreed to acquire Excellergy for up to $2B (upfront + milestones)
    • 2025-10-13: Launched with $70M Series A (Samsara BioCapital lead; Red Tree, Decheng)
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Fathom Therapeutics

  • 总部:New York, NY,USA(US)
  • 模态 / 领域:Small molecules / Undisclosed
  • 融资(2025 起):2026-04-27 Series A $47M [BioPharmaDive];累计披露 $47.0M
  • 状态:私有运营;当前阶段:Platform + preclinical: Microcosmos physics/quantum-chemistry + AI protein-dynamics engine (formerly Atommap); internal small-molecule and degrader programs, lead program in animal efficacy studies; multiple external discovery partnerships; no clinical assets.
  • 最新动态:
    • 2026-04-27: $47M oversubscribed Series A led by Sutter Hill (Chemistry, Alexandria Venture, NY Ventures); renamed from Atommap; Mandana Honu CBO, Diala Ezzeddine to board; proceeds to scale lab-in-the-loop capabilities and internal programs
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 low)
展开:证据、外部提供方、公司表态、投资人、来源

GlycoEra

  • 总部:Schlieren (Zurich),Switzerland(Europe)
  • 模态 / 领域:Biologics / Immune diseases
  • 融资(2025 起):2025-05-27 Series B $130M [BioPharmaDive];累计披露 $130.0M
  • 状态:私有运营;当前阶段:Lead GE8820 (IgG4-selective extracellular protein degrader, glycoengineered biologic) for pemphigus vulgaris / primary membranous nephropathy and other IgG4-mediated disease; FIH was planned for late 2025 - no dosing announcement found as of Nov 2026; CMO hired Jan 2026 to lead GE8820 clinical development; second program potential CTA 2026
  • 最新动态:
    • 2026-09-16: Andrea Matthews (ex-Astria CBO) appointed Chief Business Officer
    • 2026-01-08: Petra Duda MD PhD appointed CMO to lead GE8820 clinical development
    • 2025-05-27: $130M Series B led by Novo Holdings (BMS, Catalio, LifeArc among investors) to take GE8820 into clinic
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Matchpoint Therapeutics

  • 总部:Cambridge MA,US(US)
  • 模态 / 领域:Small molecules / Immune diseases
  • 融资(2025 起):2026-10-07 Series B $150M [BioPharmaDive];累计披露 $150.0M
  • 状态:私有运营;当前阶段:Lead MPT-062 (oral covalent first-in-class T-cell modulator, autoimmune/inflammatory) moving into clinic (Phase 1 start funded by Series B); ACE covalent chemoproteomics platform; Novartis-partnered transcription-factor program.
  • 最新动态:
    • 2026-10-07 $150M Series B co-led by Nextech Invest and Norwest to take MPT-062 into clinic
    • 2025-07 Novartis option/license deal: up to 60Mupfront + researchfunding, upto 1B total
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Neomorph

  • 总部:San Diego,US(US)
  • 模态 / 领域:Small molecules / Cancer
  • 融资(2025 起):2026-04-13 Series B $100M [BioPharmaDive] | 2026-04-13 Series B $100.0M [Fierce];累计披露 $100.0M
  • 状态:私有运营;当前阶段:Lead NEO-811 (molecular glue degrader) Phase 1/2 in ccRCC, first patient Feb 2026; discovery platform with AbbVie and Biogen collaborations.
  • 最新动态:
    • 2026-05-13 Robert J. Hugin appointed Chairman
    • 2026-04-13 Closed $100M Series B
    • 2026-02-03 First patient dosed in Phase 1/2 of NEO-811 in ccRCC
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:San Diego-founded; careers page shows scientists in lab and 'molecular sciences' teams; claims 'world's largest proprietary molecular glue target space' with degron, glue library and E3 ligase discovery (wet proteomics/chemistry platform).
  • 外部提供方:AbbVie (partner); Biogen (partner);中国提供方:unknown
  • 公司表态:Careers page: emphasizes 'careful experimentation' and high-quality data across discovery and development to unlock the proteome.
  • 投资人:Deerfield Management ; Deerfield Management, Alexandria Venture Investments ; Deerfield Management, Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute and others.
  • 来源:

Normunity

  • 总部:Branford CT,US(US)
  • 模态 / 领域:Biologics / Cancer
  • 融资(2025 起):2025-01-13 Series B $75M [BioPharmaDive] | 2025-01-13 Series B $75.0M [Fierce];累计披露 $75.0M
  • 状态:私有运营;当前阶段:Lead NRM-823 (T cell engager vs first-in-class 'Immuno-smart' tumor antigen) in Phase 1 (NCT07182149; recruiting, ~9 US sites, ~150 pts; Parts A dose-escalation, B expansion, C checkpoint-inhibitor combo); other biologics (antibodies, bispecifics, payload biologics) preclinical
  • 最新动态:
    • 2026-02-04: Presented at TD Cowen 46th Annual Health Care Conference
    • 2025-12 (approx.): First patient dosed in Phase 1 of NRM-823 (exact date not confirmed; trial recruiting by Feb 2026)
    • 2025-01-13: $75M Series B to advance NRM-823 into Phase 1
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:Science page splits work: Lieping Chen lab at Yale School of Medicine does discovery (target ID/validation via high-throughput phenotypic screens on human cells/tissues, engineering platforms, animal models), while Normunity does development (candidate generation, further animal testing, CMC, regulatory, clinical). About-us page describes no Normunity-owned lab; management is CEO/CDO/CFO-CBO/CSO/CTO/clinical/program roles with no bench-level research leads; no street address published (203 area code, CT); careers page lists no openings.
  • 外部提供方:Lieping Chen lab, Yale School of Medicine (discovery partner);中国提供方:unknown
  • 公司表态:Science page: discovery happens in the Lieping Chen lab and development at Normunity - an academic-biotech 'integrated engine'.
  • 投资人:Samsara BioCapital, Enavate Sciences ; Samsara BioCapital, Sanofi Ventures ; Co-led by Samsara BioCapital and Enavate Sciences, with participation from Regeneron Ventures, Pfizer Ventures, YK Bioventures, Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group and Connecticut Innovations.
  • 来源:

Nuclidium

  • 总部:Basel,Switzerland(Europe)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2025-07-10 Series B $99.0M [Fierce];累计披露 $99.0M
  • 状态:私有运营;当前阶段:Copper theranostics: 61Cu-NU101 (PSMA PET) completed Phase 1 imaging; therapeutic 67Cu-NU101 (mCRPC) and NU201 (SSTR2, metastatic breast cancer) Cu-67 therapy studies to start in coming months (per Oct 2026 NorthStar deal coverage)
  • 最新动态:
    • 2026-10-19: Long-term Cu-67 production and cGMP radiopharmaceutical manufacturing deal with NorthStar Medical Radioisotopes (Beloit, WI)
    • 2026-05: Series B extension; total Series B CHF105M; plans to expand international production/manufacturing network
    • 2025-07-10: Series B (CHF79M first close) led by Kurma Growth; expanding Munich base
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Nura Bio

  • 总部:South San Francisco,US(US)
  • 模态 / 领域:Small molecules / CNS disorders
  • 融资(2025 起):2026-06-22 Series B $74M [BioPharmaDive] | 2026-06-22 Series B $73.8M [Fierce];累计披露 $74.0M
  • 状态:私有运营;当前阶段:SARM1 inhibitor franchise: NB-4746 (oral reversible, 1st gen) completed Phase 1 HV, global Phase 1b/2a in ALS with first patient dosed; NB-9402 (covalent allosteric, 2nd gen) Phase 1a HV, completion expected 2026
  • 最新动态:
    • 2026-06-22: $73.8M Series B led by The Column Group (Euclidean, Samsara, Sanofi Ventures) for clinical proof-of-biology; first ALS patient dosed with NB-4746 in global Phase 1b/2a
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:MedCity News (Sep 2024): all Nura drugs including lead NB-4746 'were all discovered in-house'. Address 171 Oyster Point Blvd, Suite 401, South San Francisco (contact page) - a building in Healthpeak's 'The Cove at Oyster Point' lab campus (classified Lab). Site describes team as 'leading biologists, chemists, and drug developers' and 'drug hunters'. Current site lists no open roles; leadership page now shows only CEO, CMO, CBO (clinical-stage shift).
  • 外部提供方:未找到;中国提供方:unknown
  • 公司表态:CEO Shilpa Sambashivan (MedCity, 2024): as a clinical-stage company moving more molecules into the clinic, 'you're always raising'; company says its SARM1 drugs were discovered in-house.
  • 投资人:The Column Group ; Sanofi Ventures, Samsara BioCapital ; The Column Group, Euclidean Capital, Samsara BioCapital and Sanofi Ventures.
  • 来源:

PsiThera

  • 总部:Watertown MA,US(US)
  • 模态 / 领域:Undisclosed / Immune diseases
  • 融资(2025 起):2025-12-10 Series A $48M [BioPharmaDive];累计披露 $48.0M
  • 状态:私有运营;当前阶段:Discovery/preclinical: oral small molecules for TNF-superfamily immunology targets (soluble TNFa, TL1A and others) via physics-native QUAISAR platform; advancing leads toward IND-enabling studies; no clinical assets.
  • 最新动态:
    • 2025-12-10: $47.5M Series A led by Samsara BioCapital and Lightstone Ventures; renamed from Psivant Therapeutics; Eric Shaff named CEO
    • 2025-11-18: Boston Globe: Psivant took ~20,000 sq ft at 66 Galen Street lab building, Watertown
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

QuantX Biosciences

  • 总部:Princeton NJ,US(US)
  • 模态 / 领域:Small molecules / Immune diseases
  • 融资(2025 起):2026-02-09 Series B $85M [BioPharmaDive] | 2026-02-09 Series B $85.0M [Fierce];累计披露 $85.0M
  • 状态:私有运营;当前阶段:IND-enabling/late preclinical: oral STAT6 inhibitor and oral dual IL-17A/F inhibitor heading to first-in-human (Phase 1 targets Q4 2026 / Q1 2027 per first pass; no dosing confirmation found); oral TNFa inhibitor in discovery
  • 最新动态:
    • 2026-02-09: Closed oversubscribed $85M Series B co-led by LAV and Sanofi Ventures (Hongshan participating); $130M raised to date; interim CEO Wei Li (Creacion Ventures)
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Ratio Therapeutics

  • 总部:Boston,US(US)
  • 模态 / 领域:Radiopharmaceuticals / Cancer
  • 融资(2025 起):2026-07-31 Series C $70M [BioPharmaDive] | 2026-07-31 Series C $70.0M [Fierce];累计披露 $70.0M
  • 状态:私有运营;当前阶段:Lead [Ac-225]RTX-2358 (FAP-targeted alpha RLT) in ATLAS Phase 1/2 (advanced sarcomas); next-gen RLT and GRPR programs nearing clinic; partnered Novartis SSTR2 RLT; imaging assets
  • 最新动态:
    • 2026-05 Expanded CDMO agreement with PharmaLogic adding Idaho Falls production of Ac-225-RTX-2358 and multi-dose batch process
    • 2026-07-31 $70M Series C (new: Catalio, Eli Lilly, Wasatch Group; existing BMS, Duquesne) to advance ATLAS and scale manufacturing
    • 2026 Second Ac-225 source secured (Niowave)
  • wet-lab 模式:混合(hybrid,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Renasant Bio

  • 总部:California,US(US)
  • 模态 / 领域:Small molecules / Other
  • 融资(2025 起):2025-07-10 Seed $55M [BioPharmaDive] | 2025-07-10 Seed $54.5M [Fierce];累计披露 $55.0M
  • 状态:私有运营;当前阶段:Preclinical: lead oral small-molecule polycystin (PC1/2) corrector for ADPKD progressing through preclinical development; first-in-class potentiator program in discovery; no clinical trial registered.
  • 最新动态:
    • 2026-01-05: Named to BioSpace NextGen Class of 2026
    • 2025-07-10: Launched with $54.5M seed (5AM Ventures lead; Atlas, OrbiMed, Qiming USA); incubated in 5AM's 4:59 Initiative
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源
  • 证据:Corporate HQ 2630 Bancroft Way, Berkeley (Bakar Labs / Berkeley BioEnginuity Hub incubator building with shared wet-lab benches). A contract 'Research Associate, In Vivo' posting places the role at Bakar Labs, Berkeley (with support in Cambridge MA), covering rodent studies, colony management and lab operations. Launch PR says company built proprietary assays (protein trafficking, electrophysiology/polycystin channel physiology). Scientific co-founders from UCSF (Reiter, Delling). Careers page currently shows no openings.
  • 外部提供方:未找到;中国提供方:unknown
  • 公司表态:Launch PR: 'developed proprietary assays to assess protein trafficking' leveraging electrophysiology expertise; founded/incubated within 5AM's 4:59 Initiative, based in Berkeley.
  • 投资人:5 AM Ventures, Atlas Venture, OrbiMed, Qiming Venture Partners USA ; Atlas Venture, OrbiMed ; 5AM Ventures, Atlas Venture, OrbiMed and Qiming Ventures.
  • 来源:

SciNeuro Pharmaceuticals

  • 总部:Rockville, MD,USA(US)
  • 模态 / 领域:Multiple / CNS disorders
  • 融资(2025 起):2025-12-04 Undisclosed $53M [BioPharmaDive] | 2025-12-04 Series N/A $53.0M [Fierce];累计披露 $53.0M
  • 状态:私有运营;当前阶段:Multi-modality neurodegeneration pipeline: SNP318 (brain-penetrant Lp-PLA2 inhibitor) completed Phase 1 in Australia (2023); SNP614 (LNA ASO vs LRRK2, NHP data) advancing toward IND with $5M MJFF award; SNP234 aggregate-selective anti-Abeta antibody / BBB-shuttle Abeta program licensed to Novartis (Jan 2026).
  • 最新动态:
    • 2026-01-12: Exclusive worldwide license of BBB-shuttle anti-amyloid-beta antibody program to Novartis: 165Mupfront, upto 1.5B milestones, royalties
    • 2025-12-04: $53M financing led by LAV and ARCH; Hogan Wan appointed CFO
    • 2025-11-20: $5M Michael J. Fox Foundation award for LRRK2 ASO SNP614 (joins LITE program)
  • wet-lab 模式:混合(hybrid,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Setara Biosciences

  • 总部:San Diego, CA,USA(US)
  • 模态 / 领域:Small molecules / CNS disorders
  • 融资(2025 起):2026-10-30 Series A $90M [BioPharmaDive];累计披露 $90.0M
  • 状态:私有运营;当前阶段:Lead STAR-0871 (ex-ABS-0871, oral TRPV4 inhibitor): Phase 1 healthy-volunteer portion complete; Phase 1b in CMT2C patients planned (by end-2026 per BioPharma Dive; 2027 per other coverage); Phase 2a in overactive bladder planned; FDA RPD/Orphan/Fast Track. Discovery-stage programs in other rare diseases, epilepsy and migraine
  • 最新动态:
    • 2026-10-30: Launched as Setara Biosciences with $90M Series A (Deerfield, Canaan, Jazz minority stake) carrying Actio's non-ABS-1230 pipeline; David Goldstein CEO/president, David Breckenridge CSO, Cayce Denton CFO
    • 2026-09-15: Jazz completed acquisition of Actio; non-KCNT1 programs carved out into the new company
  • wet-lab 模式:自建(in_house,置信 low)
展开:证据、外部提供方、公司表态、投资人、来源

Signadori Bio

  • 总部:Paris,France(Europe)
  • 模态 / 领域:Cell or gene therapy / Cancer
  • 融资(2025 起):2026-05-06 Seed $13M [BioPharmaDive];累计披露 $13.0M
  • 状态:私有运营;当前阶段:Preclinical: off-the-shelf in vivo gene-modified monocyte immunotherapy for solid tumours; lead SiB-2101 heading to lead candidate nomination; process development with eXmoor Pharma
  • 最新动态:
    • 2026-05-06: Seed extension bringing total to EUR11.1M; Taiho Ventures joins Sofinnova and Invivo; proceeds also for expanding scientific and operational teams; Selwyn Ho is CEO
    • 2025-06-18: Collaboration with UK CGT CDMO eXmoor Pharma for technology translation, process development and eventual GMP manufacturing of lead candidate
    • 2025-04: Invivo Partners co-investment ahead of seed close
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Solu Therapeutics

  • 总部:Boston, MA,USA(US)
  • 模态 / 领域:Biologics / Cancer
  • 融资(2025 起):2025-04-05 Series A $41M [BioPharmaDive];累计披露 $41.0M
  • 状态:私有运营;当前阶段:Lead STX-0712 (CCR2-targeted CyTAC antibody-small molecule conjugate) in Phase 1 for R/R CMML (FDA Fast Track May 2026) with AML cohort dosing initiated Oct 2026; STX-0812, STX-0640 (I&I) and TicTAC NaV1.7/1.8 pain programs preclinical.
  • 最新动态:
    • 2026-10-08: Dosing initiated in AML cohort of STX-0712 Phase 1
    • 2026-05-27: FDA Fast Track designation for STX-0712 in CMML
    • 2025-06-12: Enda Moran appointed COO (CMC, quality, program management, facilities)
    • 2025-04-09: $41M Series A to complete STX-0712 dose escalation/expansion in CMML
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Storm Therapeutics

  • 总部:Cambridge,UK(Europe)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2026-04-16 Series C $56.0M [Fierce];累计披露 $56.0M
  • 状态:私有运营;当前阶段:Lead STC-15 (oral METTL3 inhibitor) Phase 2 monotherapy in select sarcomas (NCT06975293), first patient dosed Apr 2026; other RNA-modifying-enzyme programs discovery stage
  • 最新动态:
    • 2026-04-16 $56M Series C (M Ventures, Pfizer Ventures, Taiho Ventures, IP Group) and first patient dosed in Phase 2 sarcoma trial
    • 2026-01 Strategic collaboration with AlidaBio on RNA-modification cancer therapies
  • wet-lab 模式:混合(hybrid,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

TRexBio

  • 总部:San Francisco,US(US)
  • 模态 / 领域:Biologics / Immune diseases
  • 融资(2025 起):2026-01-27 Series B $50M [BioPharmaDive] | 2026-01-27 Series N/A $50.0M [Fierce];累计披露 $50.0M
  • 状态:已上市;当前阶段:Lead TRB-061 (TNFR2 agonist): Phase 1a complete (topline Aug 2026); Phase 1b in moderate-to-severe atopic dermatitis dosing since Apr 2026, data mid-2027. TRB-051 partnered with Lilly. TRB-071 and TRB-081 to Phase 1 in 2027.
  • 最新动态:
    • 2026-01-27 Closed a $50M financing.
    • 2026-08-26 TRB-061 Phase 1a topline: well tolerated, no treatment-related SAEs or DLTs.
    • 2026-10 Nasdaq IPO (TRXB) priced at $14, the low end of the range, raising about $116.6M. S-1 filed 2026-09-18.
  • wet-lab 模式:混合(hybrid,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Tectora Therapeutics

  • 总部:,US(US)
  • 模态 / 领域:Small molecules / Immune diseases
  • 融资(2025 起):2026-09-09 Series A $55M [BioPharmaDive] | 2026-09-09 Series A $55.0M [Fierce];累计披露 $55.0M
  • 状态:私有运营;当前阶段:Preclinical/discovery; two early-stage oral small-molecule I&I programs (SDGR-4594, SDGR-8139, targets undisclosed) licensed from Schrodinger, aiming for clinical candidates
  • 最新动态:
    • 2026-09-09 Launched with $55M Series A (NEA, RA Capital); licensing and collaboration agreement with Schrodinger (equity + milestones/royalties)
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Terremoto Biosciences

  • 总部:South San Francisco,US(US)
  • 模态 / 领域:Small molecules / Cancer
  • 融资(2025 起):2026-04-15 Series C $108M [BioPharmaDive] | 2026-04-15 Series C $108.0M [Fierce];累计披露 $108.0M
  • 状态:私有运营;当前阶段:Lead TER-2013 (oral lysine-targeted covalent AKT1-selective inhibitor) Phase 1/2 in AKT/PI3K/PTEN-altered solid tumors (NCT07109726, started Sep 2025), FDA Fast Track in HR+/HER2- breast cancer; TER-4480 (HHT) entering clinic 2026
  • 最新动态:
    • 2026-06-03 FDA Fast Track for TER-2013 in HR+/HER2- breast cancer
    • 2026-04-15 $108M Series C
    • 2026-08-05 Appointed James Christensen PhD as CEO
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Think Bioscience

  • 总部:Colorado,US(US)
  • 模态 / 领域:未找到 / 未找到
  • 融资(2025 起):2026-01-21 Series A $55.0M [Fierce];累计披露 $55.0M
  • 状态:私有运营;当前阶段:Preclinical; lead small molecule for Noonan syndrome (targeting causal mutations, likely SHP2/RAS-pathway phosphatase); synthetic-biology/microbial platform for cryptic pockets on phosphatases, TFs, kinases, proteases, GTPases
  • 最新动态:
    • 2026-01-20 $55M oversubscribed Series A led by Innovation Endeavors (Janus Henderson, Regeneron Ventures, CE-Ventures); total $78.25M
  • wet-lab 模式:自建(in_house,置信 high)
展开:证据、外部提供方、公司表态、投资人、来源

Triana Biomedicines

  • 总部:Lexington, MA,US(US)
  • 模态 / 领域:Small molecules / Cancer
  • 融资(2025 起):2025-12-03 Series B $120M [BioPharmaDive] | 2025-12-03 Series B $120.0M [Fierce];累计披露 $120.0M
  • 状态:私有运营;当前阶段:Lead TRI-611 (ALK-fusion molecular glue degrader, ALK+ NSCLC) in Phase 1/2 (NCT07491497); first patient dosed Mar 2026; FDA Fast Track. Earlier molecular glue programs are preclinical.
  • 最新动态:
    • 2025-12-03 $120M oversubscribed Series B to take TRI-611 to clinical proof-of-concept.
    • 2026-03-19 First patient dosed in Phase 1/2 of TRI-611; Fast Track granted late March 2026.
    • 2026-05-18 Appointed Mohan Bala as COO and expanded SAB; AACR 2026 oral presentation on TRI-611 (April).
  • wet-lab 模式:自建(in_house,置信 medium)
展开:证据、外部提供方、公司表态、投资人、来源

Trogenix

  • 总部:Glasgow,UK(Europe)
  • 模态 / 领域:Cell or gene therapy / Cancer
  • 融资(2025 起):2025-10-06 Series A $95M [BioPharmaDive];累计披露 $95.0M
  • 状态:私有运营;当前阶段:Clinical-stage: lead TGX-007 (dual-payload AAV gene therapy with Synthetic Super-Enhancer; HSV-tk prodrug enzyme + IL-12; intratumoural) in Phase I/II ADePT trial (NCT07346144, ~65 newly diagnosed and recurrent GBM pts) - first patient dosed May 2026 at NHS Lothian; Ohio State University site also open
  • 最新动态:
    • 2026-05-28: First patient dosed in Phase I/II ADePT trial of TGX-007 (NHS Lothian Edinburgh; Ohio State University Hospital)
    • 2026-04: Nature paper (CSO Steve Pollard) on preclinical model: tumour eradication in 83% of treated cases
    • 2025-10-06: GBP70M (~$95M) Series A led by IQ Capital, with Eli Lilly, Meltwind, LongeVC, Calculus Capital
  • wet-lab 模式:虚拟/外包(virtual_outsourced,置信 low)
展开:证据、外部提供方、公司表态、投资人、来源

本文为个人研究笔记,结论基于成文时可获得的公开信息;带〔估算〕〔推断〕或⚠️的数字未经独立核实。